News
FLNA
0.6220
-5.47%
-0.0360
Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes
Benzinga · 3d ago
Weekly Report: what happened at FLNA last week (1019-1023)?
Weekly Report · 5d ago
Appeals Court Vacates Class Certification in Filana Case
TipRanks · 10/20 12:38
Filana Therapeutics Announces Fifth Circuit Rules Texas District Court Misapplied Legal Standard In Class Certification
Benzinga · 10/20 12:22
Weekly Report: what happened at FLNA last week (1012-1016)?
Weekly Report · 10/19 09:31
Weekly Report: what happened at FLNA last week (1005-1009)?
Weekly Report · 10/12 09:33
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Barchart · 10/09 07:00
Weekly Report: what happened at FLNA last week (0928-1002)?
Weekly Report · 10/05 09:33
Hewlett Packard, Everpure, Filana, Ciena & Marriott Insider Shake‑Up
TipRanks · 10/03 13:00
Filana Therapeutics CEO Makes Bold Insider Move That Could Signal Big Upside
TipRanks · 10/02 02:02
Thursday 10/1 Insider Buying Report: KBDC, FLNA
NASDAQ · 10/01 17:49
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 10/01 12:05
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 09/30 21:05
Weekly Report: what happened at FLNA last week (0921-0925)?
Weekly Report · 09/28 09:31
Analysts Offer Insights on Healthcare Companies: Doximity (DOCS) and Filana Therapeutics (FLNA)
TipRanks · 09/23 16:20
Filana Gets FDA Lift Of Clinical Hold On Simufilam For TSC-Related Epilepsy; Pre-market Stock Down
NASDAQ · 09/23 09:57
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/22 21:06
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 09/22 17:06
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
Benzinga · 09/22 16:47
Filana can proceed with study as hold lifted, says Lucid Capital
TipRanks · 09/22 14:05
More
Webull provides a variety of real-time FLNA stock news. You can receive the latest news about Filana Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About FLNA
Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.